TapewireFind a company

person · Reporting owner

Fallon Marie E.

Disclosed activity across 1 company

Tapewire entity
113856
SEC CIK
0001883686

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530See remarksMay 01, 2023May 05, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Ginkgo Bioworks Holdings, Inc.

Report date May 01, 2023 · Filed May 05, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect183,010 Ending reported balance After 2023-05-02 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2023-05-01 · Exercise / conversion · Acquired 13,683 · Balance 187,026

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Row 2 · 2023-05-01 · Exercise / conversion · Acquired 3,750 · Balance 190,776

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Row 3 · 2023-05-01 · Exercise / conversion · Acquired 307 · Balance 191,083

F2: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F3: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Row 4 · 2023-05-02 · Sale · Disposed 8,073 · Balance 183,010

F4: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect357,645 Reported balance After 2023-05-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-05-01 · Exercise / conversion · Disposed 13,683 · Balance 357,645

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect172,500 Reported balance After 2023-05-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2023-05-01 · Exercise / conversion · Disposed 3,750 · Balance 172,500

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F5: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.

Class B Common StockSEC Table II · derivative / convertible securityDirect50,612 Reported balance After 2023-05-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2023-05-01 · Exercise / conversion · Disposed 307 · Balance 50,612

F3: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F6: Includes shares of Class B Common Stock that are subject to vesting conditions.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F2: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F3: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F4: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

F5: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.

F6: Includes shares of Class B Common Stock that are subject to vesting conditions.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 02, 2023 Filed May 5, 2023 00:18 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 8,073 $1.15 $9,259.73
Disclosure

SEC source: 0001127602-23-014600 · form4.xml · nonDerivative · entry 4

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183,010

F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Read SEC document
May 01, 2023 Filed May 5, 2023 00:18 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass B Common Stock · Derivative 307 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-014600 · form4.xml · derivative · entry 7

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,612

Underlying: Class A Common Stock · 307 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F6 · price: Includes shares of Class B Common Stock that are subject to vesting conditions.

F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document
May 01, 2023 Filed May 5, 2023 00:18 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 3,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-014600 · form4.xml · derivative · entry 6

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,500

Underlying: Class A Common Stock · 3,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F5 · derivative.exercise_date: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.

F5 · derivative.expiration_date: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.

Read SEC document
May 01, 2023 Filed May 5, 2023 00:18 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 13,683 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-014600 · form4.xml · derivative · entry 5

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 357,645

Underlying: Class A Common Stock · 13,683 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
May 01, 2023 Filed May 5, 2023 00:18 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 307 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-014600 · form4.xml · nonDerivative · entry 3

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,083

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document
May 01, 2023 Filed May 5, 2023 00:18 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 3,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-014600 · form4.xml · nonDerivative · entry 2

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,776

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
May 01, 2023 Filed May 5, 2023 00:18 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 13,683 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-014600 · form4.xml · nonDerivative · entry 1

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,026

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
April 03, 2023 Filed Apr 5, 2023 22:38 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 8,732 $1.27 $11,080.91
Disclosure

SEC source: 0001127602-23-012625 · form4.xml · nonDerivative · entry 4

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,343

F5 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Read SEC document
March 31, 2023 Filed Apr 5, 2023 22:38 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass B Common Stock · Derivative 307 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-012625 · form4.xml · derivative · entry 7

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,919

Underlying: Class A Common Stock · 307 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F3 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F7 · price: Includes shares of Class B Common Stock that are subject to vesting conditions.

F4 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F4 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document
March 31, 2023 Filed Apr 5, 2023 22:38 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 3,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-012625 · form4.xml · derivative · entry 6

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,250

Underlying: Class A Common Stock · 3,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F6 · derivative.exercise_date: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.

F6 · derivative.expiration_date: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.

Read SEC document
March 31, 2023 Filed Apr 5, 2023 22:38 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 13,684 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-012625 · form4.xml · derivative · entry 5

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,328

Underlying: Class A Common Stock · 13,684 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
March 31, 2023 Filed Apr 5, 2023 22:38 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 307 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-012625 · form4.xml · nonDerivative · entry 3

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F4 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document
March 31, 2023 Filed Apr 5, 2023 22:38 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 3,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-012625 · form4.xml · nonDerivative · entry 2

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,768

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Read SEC document
March 31, 2023 Filed Apr 5, 2023 22:38 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 13,684 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-012625 · form4.xml · nonDerivative · entry 1

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,018

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
March 17, 2023 Filed Mar 24, 2023 21:13 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 GrantRestricted Stock Units · Derivative 180,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-011321 · form4.xml · derivative · entry 1

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Class A Common Stock · 180,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The RSUs vest in 48 equal monthly installments beginning on April 1, 2023.

F2 · derivative.expiration_date: The RSUs vest in 48 equal monthly installments beginning on April 1, 2023.

Read SEC document
March 02, 2023 Filed Mar 3, 2023 22:15 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 7,326 $1.33 $9,736.25
Disclosure

SEC source: 0001127602-23-008805 · form4.xml · nonDerivative · entry 3

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,334

F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 22:15 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass B Common Stock · Derivative 307 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-008805 · form4.xml · derivative · entry 5

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,226

Underlying: Class A Common Stock · 307 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 22:15 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 13,683 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-008805 · form4.xml · derivative · entry 4

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 385,012

Underlying: Class A Common Stock · 13,683 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 22:15 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 307 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-008805 · form4.xml · nonDerivative · entry 2

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 22:15 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 13,683 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-008805 · form4.xml · nonDerivative · entry 1

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:20 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 6,470 $2.15 $13,904.03
Disclosure

SEC source: 0001127602-23-003407 · form4.xml · nonDerivative · entry 3

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,670

F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:20 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass B Common Stock · Derivative 306 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-003407 · form4.xml · derivative · entry 5

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,533

Underlying: Class A Common Stock · 306 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions.

Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:20 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 13,684 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-003407 · form4.xml · derivative · entry 4

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,695

Underlying: Class A Common Stock · 13,684 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:20 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 306 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-003407 · form4.xml · nonDerivative · entry 2

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:20 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 13,684 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-003407 · form4.xml · nonDerivative · entry 1

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,834

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
January 04, 2023 Filed Jan 6, 2023 23:27 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 7,900 $1.56 $12,292.40
Disclosure

SEC source: 0001127602-23-001108 · form4.xml · nonDerivative · entry 3

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,150

F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Read SEC document
January 03, 2023 Filed Jan 6, 2023 23:27 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass B Common Stock · Derivative 307 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-001108 · form4.xml · derivative · entry 5

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,839

Underlying: Class A Common Stock · 307 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions.

Read SEC document
January 03, 2023 Filed Jan 6, 2023 23:27 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 15,350 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-001108 · form4.xml · derivative · entry 4

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 412,379

Underlying: Class A Common Stock · 15,350 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
January 03, 2023 Filed Jan 6, 2023 23:27 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 307 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-001108 · form4.xml · nonDerivative · entry 2

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,050

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document
January 03, 2023 Filed Jan 6, 2023 23:27 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 15,350 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-001108 · form4.xml · nonDerivative · entry 1

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,743

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
December 02, 2022 Filed Dec 6, 2022 02:16 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 6,176 $1.94 $11,999.97
Disclosure

SEC source: 0000899243-22-037732 · doc4.xml · nonDerivative · entry 3

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,393

F3 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of securities. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.

Read SEC document
December 01, 2022 Filed Dec 6, 2022 02:16 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass B Common Stock · Derivative 307 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-037732 · doc4.xml · derivative · entry 5

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,146

Underlying: Class A Common Stock · 307 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F4 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F4 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F4 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions.

Read SEC document
December 01, 2022 Filed Dec 6, 2022 02:16 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 13,350 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-037732 · doc4.xml · derivative · entry 4

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 427,729

Underlying: Class A Common Stock · 13,350 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F2 · price: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
December 01, 2022 Filed Dec 6, 2022 02:16 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 307 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-037732 · doc4.xml · nonDerivative · entry 2

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,569

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F2 · price: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

Read SEC document
December 01, 2022 Filed Dec 6, 2022 02:16 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 13,350 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-037732 · doc4.xml · nonDerivative · entry 1

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
November 03, 2022 Filed Nov 8, 2022 02:35 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 6,279 $2.65 $16,607.96
Disclosure

SEC source: 0000899243-22-035327 · doc4.xml · nonDerivative · entry 3

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,912

F3 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of securities. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.

Read SEC document
November 01, 2022 Filed Nov 8, 2022 02:35 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass B Common Stock · Derivative 307 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-035327 · doc4.xml · derivative · entry 5

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,453

Underlying: Class A Common Stock · 307 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F5 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F5 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F5 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F6 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions.

Read SEC document
November 01, 2022 Filed Nov 8, 2022 02:35 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 13,350 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-035327 · doc4.xml · derivative · entry 4

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,079

Underlying: Class A Common Stock · 13,350 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F2 · price: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F2 · derivative.underlying_shares: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F4 · balance_after: On October 7, 2022, the Reporting Person filed a Form 4 that reported holdings of 442,161 RSUs. At that time the Reporting Person held 454,429 RSUs.

Read SEC document
November 01, 2022 Filed Nov 8, 2022 02:35 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 307 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-035327 · doc4.xml · nonDerivative · entry 2

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F2 · price: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

Read SEC document
November 01, 2022 Filed Nov 8, 2022 02:35 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 13,350 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-035327 · doc4.xml · nonDerivative · entry 1

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
October 06, 2022 Filed Oct 8, 2022 00:21 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 102,254 $3.25 $332,325.50
Disclosure

SEC source: 0000899243-22-033326 · doc4.xml · nonDerivative · entry 1

Fallon Marie E. · CIK 0001883686 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,534

F1 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 02:05 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 2,722 $3.12 $8,497.00
Disclosure

SEC source: 0000899243-22-032863 · doc4.xml · nonDerivative · entry 3

Fallon Marie E. · CIK 0001883686 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 494,217

F4 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.

Read SEC document
October 03, 2022 Filed Oct 8, 2022 00:19 UTC Amendment Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 2,722 $3.12 $8,497.00
Disclosure

SEC source: 0000899243-22-033325 · doc4a.xml · nonDerivative · entry 3

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 229,788

F4 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.

Read SEC document
October 01, 2022 Filed Oct 5, 2022 02:05 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 490,805 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-032863 · doc4.xml · derivative · entry 6

Fallon Marie E. · CIK 0001883686 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Class A Common Stock · Not disclosed shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · derivative.underlying_shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F6 · balance_after: Includes restricted stock units that are subject to vesting conditions. Includes 190,000 restricted stock units that were acquired after November 17, 2021.

Read SEC document
October 01, 2022 Filed Oct 8, 2022 00:19 UTC Amendment Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionRestricted Stock Units · Derivative 226,376 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033325 · doc4a.xml · derivative · entry 6

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 442,161

Underlying: Class A Common Stock · Not disclosed shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · derivative.underlying_shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F6 · balance_after: Includes RSUs that are subject to vesting conditions. Includes 190,000 RSUs that were acquired after November 17, 2021.

Read SEC document
October 01, 2022 Filed Oct 8, 2022 00:19 UTC Amendment Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 226,376 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033325 · doc4a.xml · nonDerivative · entry 2

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Read SEC document
September 30, 2022 Filed Oct 5, 2022 02:05 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass B Common Stock · Derivative 6,134 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-032863 · doc4.xml · derivative · entry 4

Fallon Marie E. · CIK 0001883686 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,760

Underlying: Class A Common Stock · Not disclosed shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · derivative.underlying_shares: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions.

Read SEC document
September 30, 2022 Filed Oct 5, 2022 02:05 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 6,134 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-032863 · doc4.xml · nonDerivative · entry 1

Fallon Marie E. · CIK 0001883686 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,134

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document
September 30, 2022 Filed Oct 8, 2022 00:19 UTC Amendment Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass B Common Stock · Derivative 6,134 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033325 · doc4a.xml · derivative · entry 4

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,760

Underlying: Class A Common Stock · Not disclosed shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · derivative.underlying_shares: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Excludes RSUs, which were previously reported as shares of Class B Common Stock on the Form 4 filed by the reporting person on March 14, 2022. Because the Issuer has the ability to settle such RSUs with shares of Class A Common Stock or cash upon vesting, RSUs will be reported separately from shares of Class B Common Stock in future reports.

Read SEC document
September 30, 2022 Filed Oct 8, 2022 00:19 UTC Amendment Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 6,134 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033325 · doc4a.xml · nonDerivative · entry 1

Fallon Marie E. · CIK 0001883686 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,134

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.